Atara Biotherapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$107M
Lead Investor(s):J.P. Morgan, Cowen

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Atara Biotherapeutics's estimated annual revenue is currently $36M per year.(?)
  • Atara Biotherapeutics received $127.8M in venture funding in January 2018.
  • Atara Biotherapeutics's estimated revenue per employee is $70,097
  • Atara Biotherapeutics's total funding is $107M.

Employee Data

  • Atara Biotherapeutics has 513 Employees.(?)
  • Atara Biotherapeutics grew their employee count by 15% last year.
  • Atara Biotherapeutics currently has 1 job openings.

Atara Biotherapeutics (Nasdaq: ATRA) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara's off-the-shelf, allogeneic, T cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's most advanced off-the-shelf, allogeneic T-cell immunotherapy in development, tabelecleucel, or tab-cel, is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara is also developing off-the-shelf, allogeneic ATA188 and autologous ATA190 T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Working at Atara Atara Biotherapeutics is a 260+ person publicly traded (Nasdaq: ATRA) clinical-stage biotechnology company. We are co-located by design in South San Francisco (corporate headquarters) and Southern California (R&D and manufacturing hub in northwest Los Angeles) with a newly-established European headquarters in Zug, Switzerland. Atara also has a R&D site in the Denver, Colorado area and office in New York City. Our Southern California hub is anchored by the new 90,000 sq. ft., state-of-the-art Atara T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. People at Atara are high integrity, collaborative, roll-up-your-sleeves types who are deeply committed to putting patients first and advancing medical care with demonstrated urgency. With many accomplished people at Atara, we share humility, flexibility, respect, teamwork, good judgment and being practical in our approach to advance our therapies. We each enjoy in the journey of advancing cutting edge programs, while responsibly teaching and learning together along the way. T-Cell immunotherapy peer companies: Kite Pharma / Gilead Sciences Juno Therapeutics / Celgene Bluebird bio Adaptimmune Therapeutics Cellectis SA Fate Therapeutics Bellicum Pharmaceuticals Allogene Therapeutics